Top Markets
Coin of the day
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
株式のランク #41992
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
株価
$0.00001
最終同期: 2026-08-07
時価総額
$6.42K
変化(1日)
-90.00%
変化(1年)
-90.00%
US
取引 U.S. Stem Cell, Inc. (USRM)

カテゴリー

U.S. Stem Cell, Inc.(USRM)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
U.S. Stem Cell, Inc. の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
U.S. Stem Cell, Inc. の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.97% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。